EcoDrugPlus

60s Ribosomal Protein L30

Ensembl ID : ENSCHAG00000009819
Gene Symbol: LOC105907684
3 Cross references
304 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHAG00000019976
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCHAG00000010052
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCHAG00000008739
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCHAG00000023809
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCHAG00000005973
Gene Symbol: ADRM1
1 Cross references
198 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCHAG00000008102
Gene Symbol: ADRM1
1 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCHAG00000026369
Gene Symbol: AKT1
3 Cross references
217 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCHAG00000026557
Gene Symbol: AKT1
3 Cross references
217 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCHAG00000004219
Gene Symbol: AKT2
3 Cross references
199 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCHAG00000019414
Gene Symbol: ALK
1 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCHAG00000009614
Gene Symbol: ABCC1
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).